NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01564810,Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT01564810,,UNKNOWN,"In this study, the investigators assessed the effect of Cetuximab in combination with chemotherapy in the treatment of unresectable metastatic colorectal cancer.",NO,Colorectal Neoplasms|Neoplasm Metastasis|Liver Neoplasms,DRUG: Cetuximab|DRUG: chemotherapy of mFOLFOX6 or FOLFIRI,"the rate of patients converted to resection for liver metastases, To explore whether cetuximab in combination with chemotherapy as treatment could improve the resection rate in patients with KRAS wild-type, unresectable colorectal liver-limited metastases compared with chemotherapy alone., 3 years","progression free survival, PFS will be defined as the period from the first day of cetuximab treatment or chemotherapy to the date of disease progression (PD) or to death. Patients without PD who discontinued the study for any reason is censored at the last on-study tumor assessment date., 3 years|overall survival, OS and MST will be calculated from randomization to death from any cause or the date of the last follow-up, at which point the data will be censored., 3 years|tumor response, defined as partial and complete response according to RECIST 1.0 (Response Evaluation Criteria in Solid Tumors)., 3 years",,Xu jianmin,,ALL,"ADULT, OLDER_ADULT",PHASE4,150,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-03,2006-09,2012-06,2015-09,2012-03-28,,2012-10-24,"Zhongshan Hospital, Fudan University, Shanghai, Shanghai, 200000, China",
